Deans' stroke musings: Drug candidate restores myelin and leg mobility in multiple sclerosis mouse model

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Tuesday, January 7, 2025

Drug candidate restores myelin and leg mobility in multiple sclerosis mouse model

Ask your competent? doctor if we need this post stroke for myelin problems. Doesn't know the answer.

FIRE THAT INCOMPETENT DOCTOR!

If your doctor doesn't know anything about this, you don't have a functioning stroke doctor!

Drug candidate restores myelin and leg mobility in multiple sclerosis mouse model

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in mice, the biotech announced Dec. 23.

The Texas-based company conducted the study, published in Acta Neuropathologica Communications, with a team of Canadian researchers led by George Robertson, Ph.D., from Dalhousie University in Nova Scotia.

Io now hopes to pursue the drug, called IRX4204, in multiple nervous system indications, CEO Martin Sanders, M.D., said in the release.

“The ability of IRX4204 to inhibit and functionally repair brain demyelination opens opportunities for potentially reparative treatment of brain damage in other types of neurologic conditions in which demyelination and microglial inflammation are demonstrated to play pathologic roles," Sanders said.

Sanofi flunks midphase multiple sclerosis study, dealing another blow to Denali pact

The researchers induced experimental autoimmune encephalomyelitis (EAE) in the rodents, a common model for neuroinflammation in humans with MS. The disease is caused by the erosion of a protective sheath, made of myelin, that normally surrounds nerve cells. Without this protection, nerves degrade, leading to symptoms like muscle weakness, vision problems and cognitive issues, among others.

IRX4204 binds to and activates the retinoid X receptor (RXR), a hormone receptor known to be involved in myelin repair. A previous study found that the compound reduced pro-inflammatory T cells in mice with EAE.

The approved chemotherapy drug bexarotene also binds to RXR but is not recommended for use in multiple sclerosis after a phase 2 trial found it had poor efficacy and was not well tolerated by patients.